Skip to content

Short Stature Related Distress

The Influence of Growth Hormone (GH) Therapy on Short Stature Related Distress a Prospective Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01246219
Enrollment
60
Registered
2010-11-23
Start date
2011-10-31
Completion date
2017-11-30
Last updated
2017-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Short Stature, Self Image

Keywords

Idiopathic Short stature, Self Image, GH therapy, Psychological distress

Brief summary

The research aims to provide data on gender-related psychological impact of GH (Growth Hormone)treatment. Implicit measurable psychological metrics of the therapy outcome on males are to be evaluated in a Prospective Randomized Controlled Trial. As a secondary axis of the study, the investigators aim to provide descriptive documentation of the unique distress signal manifestation implicitly shown by Idiopathic Short Stature (ISS) boys and suggest methods of early detection and measurement of such manifestations that can be used to cement guidelines for the treatment in GH.

Detailed description

Study Design: A prospective randomized, double blind, placebo controlled trial design, comparing four research groups, with 4 repeated psychological measures (before treatment, after 3 months,after 1 year, and at the end of treatment, after 4 years). The study will be divided into two segments: Segment 1:double blind, placebo controlled, will include the first 60 ISS (Idiopathic Short Stature)recruited patients. Patients in this segment will be randomized to one of the growth hormone treatment groups in a ratio of 2:1. 40 patients will be treated 4 years with GH and 20 patients will be treated with placebo at the first year of the study and will have the option to start GH treatment after one year, for a duration of 3 years. Segment 2:after the enrollment to segment 1 will end, enrollment to segment 2 will begin.Participants in segment 2 (patients with ISS and short stature) will serve as control groups and therefore will not be treated with growth hormone. Patients in Segment 2 will be evaluated only once. The 4 repeated psychological evaluations (before treatment,after 3 months, after 1 year, and at the end of treatment, after 4 years)will include the following: 1. Implicit Association Test 2. Masculine Self Image 3. Pictures Projective Test 4. The Rosenberg Self Esteem Scale-a self report measure of explicit self- esteem 5. Quality of Life Questionnaire 6. Silhouette Apperception Technique (SAT)- a self report measure assessing children's and adolescent's perception of their own body size compared with that of their age-related peers 7. Child Behavior Checklist

Interventions

DRUGGH treatment (Genotropin)

4 years treatment with GH

DRUG1 year treatment with placebo followed by optional 3 years of GH treatment

1 year treatment with placebo followed by optional 3 years of GH treatment

Sponsors

Pfizer
CollaboratorINDUSTRY
Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
MALE
Age
8 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1 Segment 1 :Boys at the age range of 8-13 years 2. Segment 2: Boys at the age range of 12-17 years 3. Tanner stage 1 (segment 1 only) 4. more than 2 SD's (standard deviation) below the average height

Exclusion criteria

1. Mental retardation, 2. Psychiatric illness, 3. Lack of informed consent\\assent. 4. Health status that required chronic treatment with steroids

Design outcomes

Primary

MeasureTime frameDescription
Psychological Distress scoreAfter 4 years of treatmentshort stature related distress score as measured by the Height Perception Pictures Test

Secondary

MeasureTime frameDescription
Perceived self image scoreAfter 4 years of treatmentPerceived self image score as measured through Single Category Implicit Association Test

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026